The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with tanruprubart at a dose of 30 mg/kg recovered to a healthy state with a score of 0 or ...

"Usually, GBS patients recover swallowing function but this has not happened yet." While the outbreak has ended in Pune, the impact lingers. Currently, 10 GBS patients remain on ventilators ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...

Hansa Biopharma AB, "Hansa" or the "Company" , today announced its interim report for January-March 2025. Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered ...